Paradoxical effects of a selective cyclooxygenase-2 inhibitor, etodolac, on proliferative changes of forestomach in alloxan-induced diabetic rats

Experimental and Toxicologic Pathology

Volumn 61, Issue 4, 2009, Pages 371-380

  Sano, Tomoya ^a   Ozaki, Kiyokazu ^a   Kodama, Yasushi ^b   Matsuura, Tetsuro ^a   Narama, Isao ^a  

^a SETSUNAN UNIVERSITY   (Japan)

^b HIROSHIMA INTERNATIONAL UNIVERSITY   (Japan)

Author keywords

Alloxan; Cyclooxygenase 2; Diabetes; Forestomach; Squamous cell carcinoma

Indexed keywords

CYCLOOXYGENASE 2; ETODOLAC; GLUCOSE;

ALLOXAN DIABETES MELLITUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL HYPERPLASIA; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIUM HYPERPLASIA; FEMALE; FORESTOMACH; GASTRITIS; GLUCOSE BLOOD LEVEL; GLUCOSURIA; HISTOPATHOLOGY; NONHUMAN; RAT; SQUAMOUS CELL; SQUAMOUS CELL CARCINOMA; STOMACH CARCINOMA; STOMACH DISEASE; STOMACH EROSION; STOMACH HYPERPLASIA; STOMACH ULCER;

ALLOXAN; ANIMALS; CELL PROLIFERATION; CYCLOOXYGENASE 2 INHIBITORS; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ETODOLAC; FEMALE; GASTRIC MUCOSA; RATS; RATS, INBRED F344; STOMACH NEOPLASMS; TIME FACTORS;

RATTUS;

EID: 67249133457     PISSN: 09402993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.etp.2008.10.009     Document Type: Article

References (38)

1. Bacon P.A. Safety profile of etodolac in the elderly population. European Journal of Rheumatology and Inflammation 14 (1994) 19-22
2. Bamba H., Ota S., Kato A., Adachi A., Itoyama S., and Matsuzaki F. High expression of cyclooxygenase-2 in macrophages of human colonic adenoma. International Journal of Cancer 83 (1999) 470-475
3. Barnes C.J., and Lee M. Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterology 114 (1998) 873-877
4. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860-867
5. Davenport H.W. Gastric mucosal hemorrhage in dogs. Effects of acid, aspirin, and alcohol. Gastroenterology 56 (1969) 439-449
6. Goldin E., Ardite E., Elizalde J.I., Odriozola A., Panes J., Pique J.M., and Fernandez-Checa J.C. Gastric mucosal damage in experimental diabetes in rats: role of endogenous glutathione. Gastroenterology 112 (1997) 855-863
7. Hayakawa T., Fujiwara Y., Hamaguchi M., Sugawa T., Okuyama M., Sasaki E., Watanabe T., Tominaga K., Oshitani N., Higuchi K., and Arakawa T. Roles of cyclooxygenase 2 and microsomal prostaglandin E synthase 1 in rat acid reflux oesophagitis. Gut 55 (2006) 450-456
8. Hirose M., Masuda A., Imaida K., Kagawa M., Tsuda H., and Ito N. Induction of forestomach lesions in rats by oral administrations of naturally occurring antioxidants for 4 weeks. Japanese Journal of Cancer Research 78 (1987) 317-321
9. Hu P.J., Yu J., Zeng Z.R., Leung W.K., Lin H.L., Tang B.D., Bai A.H., and Sung J.J. Chemoprevention of gastric cancer by celecoxib in rats. Gut 53 (2004) 195-200
10. Inoue K., Fujisawa H., Motonaga A., Inoue Y., Kyoi T., Ueda F., and Kimura K. Anti-inflammatory effects of etodolac: comparison with other non-steroidal anti-inflammatory drugs. Biological and Pharmaceutical Bulletin 17 (1994) 1577-1583
11. Kaneko M., Morimura K., Nishikawa T., Wanibuchi H., Takada N., Osugi H., Kinoshita H., and Fukushima S. Different genetic alterations in rat forestomach tumors induced by genotoxic and non-genotoxic carcinogens. Carcinogenesis 23 (2002) 1729-1735
12. Kodama Y., Ozaki K., Sano T., Matsuura T., Akagi H., and Narama I. Induction of squamous cell carcinoma of forestomach in diabetic rats by single alloxan treatment. Cancer Science 97 (2006) 1023-1030
13. Konturek P.C., Kania J., Burnat G., Hahn E.G., and Konturek S.J. Prostaglandins as mediators of COX-2 derived carcinogenesis in gastrointestinal tract. Journal of Physiology and Pharmacology 56 Suppl. 5 (2005) 57-73
14. Kroes R., and Wester P.W. Forestomach carcinogens: possible mechanisms of action. Food and Chemical Toxicology 24 (1986) 1083-1089
15. Lu H., Ouyang W., and Huang C. Inflammation, a key event in cancer development. Molecular Cancer Research 4 (2006) 221-233
16. Magari H., Shimizu Y., Inada K., Enomoto S., Tomeki T., Yanaoka K., Tamai H., Arii K., Nakata H., Oka M., Utsunomiya H., Tsutsumi Y., et al. Inhibitory effect of etodolac, a selective cyclooxygenase-2 inhibitor, on stomach carcinogenesis in Helicobacter pylori-infected Mongolian gerbils. Biochemical and Biophysical Research Communications 334 (2005) 606-612
17. Marrogi A., Pass H.I., Khan M., Metheny-Barlow L.J., Harris C.C., and Gerwin B.I. Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): in vitro antiproliferative effects of a COX-2 inhibitor. Cancer Research 60 (2000) 3696-3700
18. Mereto E., Frencia L., and Ghia M. Effect of aspirin on incidence and growth of aberrant crypt foci induced in the rat colon by 1,2-dimethylhydrazine. Cancer Letters 76 (1994) 5-9
19. Morteau O., Morham S.G., Sellon R., Dieleman L.A., Langenbach R., Smithies O., and Sartor R.B. Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. Journal of Clinical Investigation 105 (2000) 469-478
20. Nakama K., Shichinohe K., Kobayashi K., Naito K., Uchida O., Yasuhara K., and Tobe M. Spontaneous diabetes-like syndrome in WBN/KOB rats. Acta Diabetologica Latina 22 (1985) 335-342
21. Nzeako U.C., Guicciardi M.E., Yoon J.H., Bronk S.F., and Gores G.J. COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. Hepatology 35 (2002) 552-559
22. Reddy B.S., Kawamori T., Lubet R.A., Steele V.E., Kelloff G.J., and Rao C.V. Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process. Cancer Research 59 (1999) 3387-3391
23. Sano H., Kawahito Y., Wilder R.L., Hashiramoto A., Mukai S., Asai K., Kimura S., Kato H., Kondo M., and Hla T. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Research 55 (1995) 3785-3789
24. Schmassmann A., Peskar B.M., Stettler C., Netzer P., Stroff T., Flogerzi B., and Halter F. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats. British Journal of Pharmacology 123 (1998) 795-804
25. Schottenfeld D., and Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA: A Cancer Journal for Clinicians 56 (2006) 69-83
26. Sentochnik D.E., and Eliopoulos G.M. Infection and diabetes. In: Kahn C.R., Weir G.C., King G.L., Jacobson A.M., Moses A.C., and Smith R.J. (Eds). Joslin's diabetes mellitus. 4th ed (2005), Lippincott Williams & Wilkins, Boston 1017-1033
27. Shimizu N., Ikehara Y., Inada K., Nakanishi H., Tsukamoto T., Nozaki K., Kaminishi M., Kuramoto S., Sugiyama A., Katsuyama T., and Tatematsu M. Eradication diminishes enhancing effects of Helicobacter pylori infection on glandular stomach carcinogenesis in Mongolian gerbils. Cancer Research 60 (2000) 1512-1514
28. Shiotani H., Denda A., Yamamoto K., Kitayama W., Endoh T., Sasaki Y., Tsutsumi N., Sugimura M., and Konishi Y. Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide. Cancer Research 61 (2001) 1451-1456
29. Sumi N., Akitsuki S., Fujimoto S., Tawaratani T., Yoshida M., Ishibashi S., Nakazawa M., Uchimoto H., and Nomura A. A three-month oral toxicity study of etodolac in rats followed by one-month recovery test. Oyo Yakuri/Pharmacometrics 40 (1990) 491-513
30. Sumi N., Fujimoto S., Tawaratani T., Yoshida M., Ishibashi S., Nakazawa M., Uchimoto H., and Nomura A. A twelve-month oral toxicity study of etodolac in rats followed by two-month recovery test. Oyo Yakuri/Pharmacometrics 40 (1990) 561-597
31. Takahashi M., Shirai T., Fukushima S., Ito N., Kokubo T., Furukawa F., and Kurata Y. Ulcer formation and associated tumor production in multiple sites within the stomach and duodenum of rats treated with N-methyl-N′-nitro-N-nitrosoguanidine. Journal of the National Cancer Institute 67 (1981) 473-479
32. Takeda J., Kitajima K., Fujii S., Horiuchi H., Hori H., Chibana Y., Okuyama T., Tominaga K., Ichikawa K., Ono Y., Teramoto T., Ohkura Y., et al. Inhibitory effects of etodolac, a selective COX-2 inhibitor, on the occurrence of tumors in colitis-induced tumorigenesis model in rats. Oncology Reports 11 (2004) 981-985
33. Tashima K., Fujita A., Umeda M., and Takeuchi K. Lack of gastric toxicity of nitric oxide-releasing aspirin, NCX-4016, in the stomach of diabetic rats. Life Sciences 67 (2000) 1639-1652
34. Thun M.J., Namboodiri M.M., and Heath Jr. C.W. Aspirin use and reduced risk of fatal colon cancer. New England Journal of Medicine 325 (1991) 1593-1596
35. Tsuchitani M., Saegusa T., Narama I., Nishikawa T., and Gonda T. A new diabetic strain of rat (WBN/Kob). Lab Animal 19 (1985) 200-207
36. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature: New Biology 231 (1971) 232-235
37. Wang D., Mann J.R., and DuBois R.N. The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology 128 (2005) 1445-1461
38. Yamamoto K., Kitayama W., Denda A., Morisaki A., Kuniyasu H., Inoue M., and Kirita T. Suppressive effects of a selective cyclooxygenase-2 inhibitor, etodolac, on 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis. Experimental and Toxicologic Pathology 56 (2004) 145-151